Get started
Author

Andrey Anatolyevich Shuldyakov

Observed names: A A Shul’dyakov, A Shuldyakov, A. A. SHULDYAKOV, A. A. Shul'dyakov, A. A. Shuldyakov, A.A. Shuldyakov, Andrey A. Shuldyakov, Andrey A. Shuldyakov, Andrey Shuldyakov, А A Shuldyakov, А.А. Shuldyakov, Шульдяков Андрей Анатольевич
ORCID: 0000-0002-3009-9262
Observed ORCID: 0000-0002-3009-9262
OpenAlex ID: A5059630515
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
2013 · Pedro Cahn, Anton L Pozniak, et al. · The Lancet · 531
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
2018 · Jean-Michel Molina, Kathleen Squires, et al. · The Lancet HIV · 155
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial
2019 · Jean-Michel Molina, Kathleen Squires, et al. · The Lancet HIV · 100
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials
2023 · Chloe Orkin, Jean-Michel Molina, et al. · The Lancet HIV · 38
Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials
2019 · Erkki Lathouwers, Eric Y Wong, et al. · AIDS Research and Human Retroviruses · 16
PDF
Mental Health of Medical Workers During the COVID-19 Pandemic in Russia: Results of a Cross-Sectional Study
2020 · E.V. Bachilo, J.B. Barylnik, et al. · medRxiv · 13
PDF
Use of succinate-containing agents in the treatment of infectious diseases
2016 · E O Tikhonova, E P Lyapina, et al. · Terapevticheskii arkhiv · 12
PDF
Results and Prospects of Interferone Inducers Using in Infectious Diseases Treatment
2013 · F. I. Ershov, A. A. Shul'dyakov, et al. · Annals of the Russian academy of medical sciences · 7
PDF
The efficacy of remaxol as a hepatoprotective agent in long-term psychopharmacotherapy
2019 · N. V. Filippova, Yu. B. Barylnik, et al. · S S Korsakov Journal of Neurology and Psychiatry · 6
The Clinical Manifestation of Hiv Infection Simulating Rheumatic Diseases
2018 · E. Yu. Ponomareva, A. A. Shuldyakov, et al. · Rheumatology Science and Practice · 5
PDF
Clinical and epidemiological efficacy of antiviral drug Ingavirin
2012 · A. A. Shuldyakov, E. P. Lyapina, et al. · PULMONOLOGIYA · 4
PDF
Pathogenetic approaches to the correction of vascular homeostasis in patients with COVID-19: A review
2023 · Andrey A. Shuldyakov, Anna N. Smagina, et al. · Terapevticheskii arkhiv · 3
PDF
Derivatives of acridone acetic acid in pediatric practice
2019 · A. A. Shuldyakov, E. P. Lyapina, et al. · Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) · 3
PDF
Efficacy and Safety of a New Selective Oral Factor Xa Inhibitor Amidine Hydrochloride for Prevention of Thromboembolic Events in Hospitalized Patients with COVID-19: a Multiple-Center Prospective Randomized Controlled Study
2024 · I.A. Suchkov, N.D. Mzhavanadze, et al. · Journal of Venous Disorders · 2
Retrospective Cross-Sectional Epidemiological Study of Human Papillomavirus-Associated Precancers and Anogenital Warts in Patients Attending Specialized Clinics in Russian Federation
2024 · Nikolay I. Briko, Platon D. Lopukhov, et al. · Annals of the Russian academy of medical sciences · 2
PDF
Rehabilitation of Patients After Covid-19 With Minor (predemental) Cognitive Disorders
2023 · N.V. Filippova, A.A. Shuldyakov, et al. · Современные проблемы науки и образования · 2
PDF
Infections, pandemics and sleep disorders
2021 · O.V. Kolokolov, E.A. Salina, et al. · S S Korsakov Journal of Neurology and Psychiatry · 2
Agomelatine in the treatment of major depressive disorder: assessment of the efficacy and tolerability
2019 · N. V. Filippova, Yu. B. Barylnik, et al. · S S Korsakov Journal of Neurology and Psychiatry · 2
Infections, Pandemics, and Sleep Disorders
2022 · O. V. Kolokolov, E. A. Salina, et al. · Neuroscience and Behavioral Physiology · 1
PDF
Clinical characteristics and mechanisms underlying the development of organ pathology in patients with chronic brucellosis
2021 · E.P. Lyapina, A.A. Shuldyakov, et al. · Infekcionnye bolezni · 1
Chronic brucellosis: improvement of therapy
2019 · E.P. Lyapina, A.A. Shuldyakov, et al. · Infekcionnye bolezni · 1
Principles of Andragogy in Medical Education
2015 · M. G. Romantsov, O. V. Shamsheva, et al. · DOAJ (DOAJ: Directory of Open Access Journals) · 1
1617Safety, Tolerability, and Antiretroviral Activity of Raltegravir in HIV-1 Infected Russian Children and Adolescents – a 24 Week Study
2014 · Hedy Teppler, Andrey Shuldyakov, et al. · Open Forum Infectious Diseases · 1
PDF
Periodontitis in HIV patients
2011 · А. О. Осеева, Л. А. Соболева, et al. · Саратовский научно-медицинский журнал · 1
Pathogenetic and therapeutic approaches to the correction of neurocognitive disorders in patients with chronic brucellosis
2025 · Andrey A. Shuldyakov, Anna N. Smagina, et al. · Terapevticheskii arkhiv
PDF
Works count: 38
Citation count: 909
H-index: 7
I10-index: 7
Year
Topic
Type